Chest
Selected ReportsProgressive Portopulmonary Hypertension After Liver Transplantation Treated With Epoprostenol
Section snippets
Case Report
A 32-year-old white woman was referred to the Advanced LungDisease Service at the Cleveland Clinic Foundation forprogressive dyspnea. When she was 14 years old, she had received adiagnosis of seronegative chronic active hepatitis, based on a liverbiopsy. At the age of 23 years, she had undergone a splenorenal shuntfor symptomatic esophageal varices. At age 27 years, she had undergonean uncomplicated OLT, with shunt removal and intraoperativesplenectomy. The results of a preoperative
Discussion
Portopulmonary hypertension is an uncommon syndrome that occurs in< 2% of patients with portal hypertension and is present in bothcirrhotic and noncirrhotic liver disease.6 The prognosisof PPHTN is poor, with a mean survival of 15 months afterdiagnosis.1 The histologic picture of PPHTN is similar tothat of primary pulmonary hypertension (ie, medialhypertrophy, intimal fibrosis, and plexogenic pulmonaryarteriopathy).7 The pathogenesis of PPHTN is poorlyunderstood, although several mechanisms
Conclusions
PPHTN is a rare disease with a high mortality rate and limitedtreatment options. Epoprostenol has been used to treat PPHTN and hasbeen used as a bridge to OLT. With improvement of hepatocellularfunction and reversal of portosystemic shunts, PPHTN is potentiallyreversible after OLT. However, PPHTN may persist, progress, or developafter OLT. This case report illustrates the use of epoprostenol as adefinitive treatment for PPHTN that progresses after transplantation.With the availability of
References (17)
- et al.
Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations
J Am Coll Cardiol
(1991) - et al.
Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics
Gastroenterology
(1991) - et al.
Pulmonary hypertension in chronic liver disease
Clin Chest Med
(1996) - et al.
Improvement of pulmonary hypertension after liver transplantation
Chest
(1999) - et al.
Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients
Mayo Clin Proc
(1996) - et al.
Severe pulmonary hypertension in liver transplant candidates
Liver Transplant Surg
(1997) - et al.
Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension
Transplantation
(1997) - et al.
Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension
Hepatology
(1999)
Cited by (48)
Struggling Between Liver Transplantation and Portopulmonary Hypertension
2023, Heart Failure ClinicsPortopulmonary Hypertension: The Interplay Between the Liver and Pulmonary Arteries
2022, Heart Lung and CirculationTreatment of Portopulmonary Hypertension (PoPH): A review
2022, Journal of Liver TransplantationRapid Normalization of Portopulmonary Hypertension After Living Donor Liver Transplantation
2009, Transplantation ProceedingsCitation Excerpt :Literature reviews have suggested that most patients with PPHTN show improved or normalized pulmonary artery pressures, although this may take up to 2 years.15 Nevertheless, persistence, progression, recurrence, and even de novo evolution of pulmonary hypertension after OLT have also been observed.13,15–18 It is noteworthy that the present case represents the most rapid response among those who showed normalized hemodynamics in the postoperative period.
Hemodynamic Profile of Portopulmonary Hypertension
2009, Transplantation ProceedingsCitation Excerpt :When evaluating a candidate with PPHTN for OLT it should be considered that resolution of symptoms following OLT may take months or longer. Persistence, or even progression of disease, has also been reported.27 This implies that both the patient and the transplanted graft have to face an increased pressure in the right heart chambers for a long time as well as the delayed or incomplete remodeling of pulmonary vasculature.
Portopulmonary hypertension: State of the art
2008, Annals of HepatologyCitation Excerpt :For LT candidates with documented moderate to severe POPH (mPAP > 35 mmHg) who will have vasodilator therapy initiated, the goal of therapy should be to reduce the mPAP to < 35 mmHg and the PVR < 400 dynes/ s/cm-5 before proceeding to LT.3 The reason for this cutoff is that previous data have demonstrated no increased mortality risk when the mPAP is < 35 mmHg.9,27 A recent report from Sussman and coworkers,71 demonstrated that in 8 patients with POPH as their only contraindication for LT, pretreatment with intravenous epoprostenol caused a significant improvement in their hemodynamics, allowing 75% to be listed for LT. There have been reports of persistence of progression of PAH even after LT.72,73 Recurrence of PAH following failure of the transplanted liver can also occur.74 A multicenter database was organized at 10 LT referral centers to identify the outcome of patients with POPH being evaluated for LT between 1996 and 2001.67